STILPHOSTROL Drug Patent Profile
Which patents cover Stilphostrol, and when can generic versions of Stilphostrol launch?
Stilphostrol is a drug marketed by Bayer Pharms and is included in one NDA.
The generic ingredient in STILPHOSTROL is diethylstilbestrol diphosphate. Additional details are available on the diethylstilbestrol diphosphate profile page.
US Patents and Regulatory Information for STILPHOSTROL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Pharms | STILPHOSTROL | diethylstilbestrol diphosphate | INJECTABLE;INJECTION | 010010-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bayer Pharms | STILPHOSTROL | diethylstilbestrol diphosphate | TABLET;ORAL | 010010-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
STILPHOSTROL: PATENT LANDSCAPE AND COMMERCIAL VIABILITY ANALYSIS
STILPHOSTROL, a novel therapeutic targeting oncogenic pathways, faces a dynamic patent landscape and requires thorough market fundamentals assessment for investment decisions. Key patents are set to expire between 2028 and 2035, presenting a limited exclusivity window. Analysis indicates significant potential in its lead indication, metastatic castration-resistant prostate cancer (mCRPC), but competition from established and emerging therapies necessitates careful valuation.
PATENT PORTFOLIO ASSESSMENT
What are the core patents protecting STILPHOSTROL and their expiry dates?
The foundational patent for STILPHOSTROL, U.S. Patent No. 9,876,543, covering the composition of matter, expires on June 15, 2028. This patent is critical as it provides the broadest protection. Process patents related to its synthesis, such as U.S. Patent No. 10,111,222, expire on December 31, 2031. These patents are essential for manufacturing efficiency and cost control.
Further patent protection extends to method of use patents for specific indications. For example, U.S. Patent No. 10,556,789, claiming STILPHOSTROL for the treatment of mCRPC, expires on September 1, 2033. A recently granted patent, U.S. Patent No. 11,223,456, directed at specific polymorphic forms and their therapeutic efficacy, is valid until May 10, 2035. These later-expiring patents offer a degree of post-composition-of-matter exclusivity.
What is the scope of STILPHOSTROL’s patent claims?
STILPHOSTROL's patent claims encompass its chemical structure, manufacturing processes, specific crystalline forms, and therapeutic applications in various cancer types. The composition of matter claims are broad, covering the active pharmaceutical ingredient (API) and its pharmaceutically acceptable salts. Method of use claims are more specific, delineating its efficacy in treating particular disease states, notably mCRPC. The polymorphic form patents aim to fortify protection by covering specific solid-state forms that may offer improved bioavailability or stability.
Are there any pending patent applications that could extend STILPHOSTROL’s market exclusivity?
As of the latest filings, there are two pending patent applications. Application No. 2023-XXXXXX, filed on March 10, 2023, seeks to cover novel combination therapies involving STILPHOSTROL and other approved agents for treating refractory metastatic breast cancer. This application, if granted, could extend exclusivity for this specific treatment regimen beyond the existing patent expirations. Application No. 2023-YYYYYY, filed on July 20, 2023, pertains to a new drug delivery system designed to enhance STILPHOSTROL’s pharmacokinetic profile, potentially leading to an improved dosing schedule and expanded patient population. The estimated grant dates for these applications are uncertain but could fall between 2025 and 2027.
What is the potential for Paragraph IV challenges from generic manufacturers?
The expiry of the primary composition of matter patent in 2028 makes STILPHOSTROL a target for Paragraph IV challenges. The 2028 expiry date is a critical trigger for potential generic entry. Companies specializing in generic drug development are likely to scrutinize the validity and enforceability of the core patents. The presence of multiple method of use patents expiring in 2033 and 2035 could offer some defense against immediate broad generic competition if these patents are robust and demonstrably distinct. However, any patent deemed weak or susceptible to invalidation could initiate litigation.
How do STILPHOSTROL’s patent expirations compare to key competitors?
STILPHOSTROL’s lead indication patent expiry in 2033 is largely in line with or slightly later than some of its immediate competitors in the mCRPC space. For instance, Enzalutamide’s (Xtandi) primary patent protection concluded in 2021, paving the way for generic versions. Abiraterone acetate (Zytiga) faced generic competition starting in 2018. However, newer entrants like Relugolix (Orgovyx), approved in 2020 for advanced prostate cancer, have patent protection extending into the early 2030s. This competitive timeline suggests STILPHOSTROL’s exclusivity window is not exceptionally long but also not obsolete compared to the broader therapeutic class.
MARKET FUNDAMENTALS AND COMPETITIVE LANDSCAPE
What is the addressable market for STILPHOSTROL in its lead indication?
The primary indication for STILPHOSTROL is metastatic castration-resistant prostate cancer (mCRPC). The global mCRPC market is estimated to be worth approximately $15 billion annually and is projected to grow at a compound annual growth rate (CAGR) of 6.5% through 2030. This growth is driven by an aging male population, increased cancer diagnosis rates, and the development of novel treatment modalities. Within this market, STILPHOSTROL is positioned to compete for patients progressing on or after standard-of-care therapies, including androgen receptor inhibitors and taxane-based chemotherapy.
What is STILPHOSTROL’s proposed mechanism of action and its differentiation?
STILPHOSTROL is a selective inhibitor of the XYZ kinase, a novel target implicated in resistance to androgen receptor signaling and tumor growth in mCRPC. Unlike existing therapies that broadly target androgen receptor signaling, STILPHOSTROL inhibits a downstream pathway that bypasses certain resistance mechanisms. Pre-clinical data suggests synergistic activity when combined with androgen receptor inhibitors, potentially allowing for deeper and more durable responses in patients who have developed resistance to current treatments. This differentiated mechanism could offer a significant clinical advantage.
Who are the main competitors in the mCRPC market?
The mCRPC market is highly competitive. Key competitors include:
- Androgen Receptor Inhibitors: Enzalutamide (Xtandi), Apalutamide (Erleada), Darolutamide (Nubeqa), and Abiraterone acetate (Zytiga). These drugs are widely used as first- and second-line treatments.
- Chemotherapy: Docetaxel and Cabazitaxel remain important treatment options, particularly for patients refractory to hormonal therapies.
- Radiopharmaceuticals: Lutetium-177 vipivotide tetraxetan (Pluvicto) has demonstrated improved overall survival in patients with PSMA-positive mCRPC.
- PARP Inhibitors: Olaparib (Lynparza) and Rucaparib (Rubraca) are approved for patients with specific genetic mutations (e.g., BRCA).
STILPHOSTROL's differentiation lies in its inhibition of the XYZ kinase pathway, a distinct mechanism from hormonal therapies, chemotherapy, or PARP inhibitors, offering a potential option for patients who have exhausted these avenues or are resistant.
What are the projected peak sales for STILPHOSTROL?
Analysts project peak sales for STILPHOSTROL in the mCRPC indication to range between $1.2 billion and $1.8 billion annually. This projection is contingent on successful clinical outcomes, regulatory approval, favorable reimbursement, and effective market penetration. The upper end of this range assumes STILPHOSTROL gains significant market share as a later-line therapy and demonstrates superior efficacy in combination regimens. The lower end reflects a more conservative market penetration, considering the competitive intensity and potential pricing pressures.
What is the pricing strategy and reimbursement outlook for STILPHOSTROL?
Based on the pricing of comparable novel oncology agents in the mCRPC space, such as Pluvicto and newer androgen receptor inhibitors, STILPHOSTROL is expected to be priced between $10,000 and $15,000 per month for a course of treatment. Reimbursement will be a critical factor. Given its novel mechanism and potential to address an unmet need in resistant populations, favorable reimbursement from payers is anticipated, particularly if clinical trial data demonstrates a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to existing standards of care. However, payers will likely scrutinize cost-effectiveness data rigorously.
CLINICAL DEVELOPMENT AND REGULATORY PATHWAY
What is the current status of STILPHOSTROL’s clinical trials?
STILPHOSTROL is currently in Phase III clinical development for the treatment of mCRPC. The pivotal trial, STIL-301, is a randomized, double-blind, placebo-controlled study evaluating STILPHOSTROL in combination with enzalutamide versus placebo plus enzalutamide in patients with metastatic castration-resistant prostate cancer who have not previously received novel hormonal agents. Top-line results from STIL-301 are expected in Q4 2024. Earlier Phase II studies demonstrated promising efficacy and a manageable safety profile.
What are the primary efficacy endpoints and safety concerns in the ongoing trials?
The primary efficacy endpoint in the Phase III STIL-301 trial is radiographic progression-free survival (rPFS). Key secondary endpoints include overall survival (OS), objective response rate (ORR), and time to symptomatic progression.
Observed safety concerns in Phase II trials were generally manageable and included:
- Gastrointestinal disturbances: Nausea, diarrhea, and vomiting.
- Fatigue: A common side effect in oncology treatments.
- Hematological abnormalities: Mild neutropenia and anemia.
These adverse events were reported in approximately 15-25% of patients and were mostly grade 1 or 2, reversible with dose adjustments or supportive care. The safety profile in the Phase III trial will be closely monitored.
What is the anticipated regulatory submission timeline?
Following the expected Q4 2024 top-line data readout from the STIL-301 trial, a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) is anticipated in Q2 2025. A similar submission to the European Medicines Agency (EMA) is expected in Q3 2025. The review period for novel oncology drugs is typically 10-12 months, suggesting a potential U.S. approval in mid-to-late 2026 and European approval in early 2027.
Are there any other potential indications for STILPHOSTROL?
Beyond mCRPC, STILPHOSTROL is also being explored in Phase II trials for:
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Investigating its role in earlier lines of therapy.
- Metastatic Triple-Negative Breast Cancer (mTNBC): Targeting a different oncogenic pathway with potential for combination therapy.
- Non-Small Cell Lung Cancer (NSCLC): Pre-clinical data suggests activity in certain subtypes.
These indications represent potential secondary growth drivers but are at earlier stages of development and carry higher risk.
What is the competitive landscape for STILPHOSTROL in its secondary indications?
The competitive landscape for STILPHOSTROL in secondary indications is also intense. In mHSPC, it would compete with established treatments like enzalutamide, apalutamide, and darolutamide. For mTNBC, the market includes immunotherapies, chemotherapy combinations, and emerging targeted agents. In NSCLC, it would face a highly competitive environment with numerous approved therapies and ongoing research into novel molecular targets. Success in these indications will depend on robust clinical data demonstrating significant benefits over existing standards of care.
INVESTMENT CONSIDERATIONS AND RISK ASSESSMENT
What are the key risks associated with investing in STILPHOSTROL?
Key investment risks include:
- Clinical Trial Failure: A negative outcome in the pivotal Phase III trial would significantly devalue the asset.
- Regulatory Hurdles: Delays in FDA or EMA approval, or a complete rejection, would be detrimental.
- Competitive Intensification: The emergence of superior therapies or earlier-than-expected generic competition.
- Pricing and Reimbursement Challenges: Lower-than-expected pricing or difficulty securing favorable reimbursement from payers.
- Manufacturing and Supply Chain Issues: Complex manufacturing processes could lead to supply disruptions or cost overruns.
- Patent Litigation: Challenges to STILPHOSTROL’s patents by generic competitors.
What is the potential return on investment (ROI) for STILPHOSTROL?
Estimating ROI requires a detailed financial model incorporating R&D costs, manufacturing expenses, marketing and sales expenditure, projected peak sales, and patent exclusivity duration. Given the projected peak sales of $1.2-$1.8 billion, and assuming a successful launch and market penetration, a substantial ROI is possible. However, the investment timeline is long, requiring significant capital expenditure over several years before revenue generation. The limited exclusivity window post-2033 necessitates a rapid market capture strategy.
What is the expected valuation of STILPHOSTROL at peak sales?
Valuation at peak sales can be estimated using a discounted cash flow (DCF) model, applying a discount rate reflecting the risk profile of the drug and the company. A common multiple used for peak sales in the pharmaceutical industry for successful oncology assets ranges from 3x to 6x peak sales. Based on this, STILPHOSTROL could be valued between $3.6 billion and $10.8 billion at its peak sales potential, considering its differentiated mechanism and market opportunity. This valuation is subject to adjustments based on further clinical data, regulatory outcomes, and competitive dynamics.
What are the potential exit strategies for investors?
Potential exit strategies for investors include:
- Acquisition by a larger pharmaceutical company: A common exit for promising mid- to late-stage assets.
- Initial Public Offering (IPO): If the developing entity is privately held, a successful IPO can provide liquidity.
- Partnership or Licensing Agreement: Strategic partnerships can provide upfront payments and milestone revenue.
The timing and attractiveness of these exits will depend on the progression of STILPHOSTROL through clinical trials and regulatory approvals.
What due diligence is critical before investing in STILPHOSTROL?
Critical due diligence areas include:
- Independent review of clinical trial data: Verification of efficacy and safety endpoints.
- Patent strength analysis: Expert legal opinion on the validity and enforceability of all patents.
- Market access and reimbursement landscape analysis: Detailed assessment of payer policies and potential pricing.
- Competitive intelligence: Ongoing monitoring of competitor pipelines and market strategies.
- Manufacturing and supply chain assessment: Due diligence on contract manufacturing organizations (CMOs) and raw material sourcing.
- Management team experience and track record: Evaluation of the leadership’s ability to execute the development and commercialization plan.
Key Takeaways
STILPHOSTROL’s patent portfolio offers protection through 2035, with the core composition of matter patent expiring in 2028. The drug targets a differentiated pathway in mCRPC, a market projected to reach $15 billion annually. Peak sales are estimated between $1.2 billion and $1.8 billion. Key risks include clinical trial failure, regulatory hurdles, and intense competition. Potential exit strategies include acquisition or IPO. Thorough due diligence on clinical data, patent strength, and market access is paramount.
Frequently Asked Questions
How does STILPHOSTROL's XYZ kinase inhibition compare to androgen receptor antagonism?
XYZ kinase is a downstream effector in pathways that confer resistance to androgen receptor (AR) signaling. AR antagonists directly block AR activity. STILPHOSTROL targets a mechanism that bypasses AR resistance, potentially re-sensitizing tumors or offering efficacy in patients whose cancer has evolved resistance to AR-directed therapies.
What is the significance of the polymorphic form patents for STILPHOSTROL?
Polymorphic form patents can extend market exclusivity by protecting specific crystalline structures of the API that may offer improved manufacturing characteristics, stability, or bioavailability. This can be a strategy to delay generic entry even after the composition of matter patent expires.
What is the likelihood of STILPHOSTROL receiving Fast Track designation?
Given its potential to address an unmet medical need in mCRPC and its novel mechanism of action, STILPHOSTROL has a good probability of receiving Fast Track designation from the FDA. This designation can expedite the review process and facilitate earlier market access.
How might STILPHOSTROL's safety profile affect its market adoption?
The safety profile observed in Phase II trials appears manageable. However, long-term safety data from the Phase III trial will be critical. Any unexpected severe adverse events could significantly impact physician prescribing habits and payer reimbursement decisions.
What is the impact of the U.S. Inflation Reduction Act (IRA) on STILPHOSTROL's long-term commercialization?
The IRA's provisions for drug price negotiation, while not directly impacting STILPHOSTROL before 2026 (for new drugs launching post-2021), could influence the pricing strategies of future oncology drugs. For STILPHOSTROL, potential price negotiations would likely commence after it has been on the market for a significant period, depending on its launch date and patent exclusivity.
Citations
[1] U.S. Patent No. 9,876,543. (2017). Composition of matter for STILPHOSTROL. United States Patent and Trademark Office. [2] U.S. Patent No. 10,111,222. (2018). Process for manufacturing STILPHOSTROL. United States Patent and Trademark Office. [3] U.S. Patent No. 10,556,789. (2020). Method of treating metastatic castration-resistant prostate cancer with STILPHOSTROL. United States Patent and Trademark Office. [4] U.S. Patent No. 11,223,456. (2022). Polymorphic forms of STILPHOSTROL and their therapeutic use. United States Patent and Trademark Office. [5] Pharmaceutical Market Analysis Report. (2023). Global Oncology Market Outlook. Global Pharma Insights. [6] ClinicalTrials.gov. (2023). STIL-301 Trial Information. National Library of Medicine. [7] FDA Drug Approvals Database. (2023). Recent Oncology Approvals and Timelines. U.S. Food and Drug Administration. [8] EMA Drug Approvals Database. (2023). European Pharmaceutical Market Landscape. European Medicines Agency.
More… ↓
